Effectiveness of Guideline-based Initial Enoxaparin Dosing in Achieving Therapeutic Anti-Factor Xa Levels in Pediatric Patients
Published
October 15, 2026
Paper ID
PAP-000317
Status
Published
DOI
10.65712/tmj.2123946
Advance Services
Abstract
Background: Enoxaparin is commonly used to treat pediatric patients with thrombosis due to its favourable safety profile. Enoxaparin monitoring for pediatric patients is accomplished through anti-Xa monitoring. The American College of Chest Physicians (CHEST) recommend enoxaparin for the treatment of thrombotic conditions at a dosage of 1.5 mg/kg every 12 hours for patients under 2 months, and 1 mg/kg every 12 hours for those older than 2 months of age.
Aims/Objectives: To evaluate the initial dosing of enoxaparin in achieving therapeutic anti-Xa levels, to determine the optimal dose required to attain target anti-Xa levels (0.5–1.0 units/mL), to evaluate the time of thrombosis resolution and to assess adverse events (minor, major and HIT).
Methods: A retrospective chart review of all pediatric patients (below 16-year-old) presented to Sheikha Khalifa Medical City and received enoxaparin for treatment of thrombosis between January 2020 and December 2024. Patients excluded if they received enoxaparin for prophylaxis, had creatinine clearance < 30 ml/min/1.73 m2 (using Bedside Schwartz), or had improper timing of anti-Xa level withdrawal (steady state, within 4-6 hours post dose). Demographic data (age and gender), indication (central line-associated thrombosis, venous thrombosis, intracardiac thrombosis, arterial thrombosis), critical care illness, initial anti-Xa level at steady state, initial enoxaparin dose in mg/kg, and subsequent enoxaparin dose that achieved therapeutic target were all collected. Data will be entered and analysed using the Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, IBM Corp., Version 25, Armonk, NY). All categorical variables will be reported as frequencies and percentages, while continuous variables will be reported as mean ± SD. Study approved by IRB (Institutional Review Board) (#RS-908).
Results: This retrospective analysis included 102 pediatric patients treated with enoxaparin. Most patients were male (58.5%) and admitted to the PICU (72.5%), with the largest proportion in the 6–16 years age group. Initial enoxaparin dosing adhered to CHEST guidelines in all cases. Therapeutic anti-Xa levels were achieved in 37.3% of patients after the initial dose. Subtherapeutic levels were most common among neonates (88.9%) and infants (81.8%), whereas older children achieved therapeutic levels more frequently (55.6%) (p = 0.015). Gender, critical illness, and bleeding risk were not significantly associated with anti-Xa target attainment.
The average enoxaparin dose adjustment across the cohort was 36.3%, resulting in an increase from a mean initial dose of 1.05 ± 0.21 mg/kg to a mean therapeutic dose of 1.44 ± 0.86 mg/kg (p < 0.001). The highest mean dose escalation was observed among children aged 1–5 years (71.1%), followed by infants aged 3–12 months (37.1%), while neonates (<1 month) and young infants (1–2 months) required moderate increases of 31.5% and 32.5%, respectively. Adolescents (6–16 years) exhibited minimal dose modification (9.3%).
Conclusion: Standard enoxaparin dosing often fails to achieve therapeutic anti-Xa levels in pediatric patients, especially neonates and infants. Individualized dosing guided by age-related pharmacokinetic differences is essential. Despite dose adjustments, enoxaparin showed a favorable safety profile. These findings support age-adapted protocols and routine anti-Xa monitoring to optimize efficacy and minimize complications.
Introduction
Enoxaparin, a low molecular weight heparin (LMWH), has seen a marked increase in utilization within the pediatric population for the therapeutic management of thromboembolic disorders.1 Its mechanism of action involves potentiation of antithrombin III activity, resulting in the irreversible inhibition of activated factor Xa and subsequent suppression of thrombin generation and fibrin clot formation.3
Compared to unfractionated heparin (UFH), enoxaparin demonstrates several pharmacological advantages, including superior subcutaneous bioavailability, reduced protein binding, fewer drug–drug interactions, an extended elimination half-life permitting twice-daily dosing, and a predictable dose–response relationship that obviates the need for continuous laboratory monitoring in most cases 1,2.
Despite these benefits, pediatric patients, particularly neonates and infants exhibit greater inter-individual variability in anticoagulant response when dosed on a weight-based basis, as compared to adult populations. This variability is attributed to age-dependent differences in the pharmacokinetics and pharmacodynamics of enoxaparin, including faster renal clearance and altered volume of distribution in younger children 2,3,4&5.
Current guidelines from the American College of Chest Physicians (CHEST) and the American Society of Hematology (ASH) recommend treatment dosing of enoxaparin at 1.5 mg/kg every 12 hours for infants aged ≤2 months and 1 mg/kg every 12 hours for children >2 months of age. The therapeutic goal is to attain peak anti-factor Xa activity within the range of 0.5 to 1.0 IU/mL, typically measured 4 to 6 hours post-dose at steady-state, achieved after the third or fourth administration 6,7. Nevertheless, clinical data have demonstrated that a substantial proportion of pediatric patients fail to reach this therapeutic range with guideline-based initial dosing, raising concerns about potential under-anticoagulation and suboptimal clinical outcomes 1,8.
Although the use of enoxaparin in pediatrics remains off-label, its safety profile has been well-documented. Reported rates of major bleeding in stable pediatric populations range from 0% to 5%, while minor bleeding events have been observed in approximately 16% of cases. Importantly, there have been no significant reports of heparin-induced thrombocytopenia (HIT), osteoporosis, or hypersensitivity reactions in this demographic 1,2.
Conversely, the pediatric population, particularly neonates and infants, exhibits enhanced renal clearance of enoxaparin compared to adults, necessitating a potential increase in dosing to achieve pharmacodynamic targets 4,9.
Therefore, the primary objective of this study is to evaluate the adequacy of guideline-recommended initial treatment dosing of enoxaparin in achieving target therapeutic anti-Xa levels in pediatric patients, with the intent to inform dose optimization strategies and enhance clinical efficacy.
Materials and Methods
This single-center retrospective study was conducted at Sheikh Khalifa Medical City following approval from the Institutional Review Board (#RS-908). Pediatric patients aged ≤16 years who were hospitalized between January 2020 and December 2024 and received therapeutic enoxaparin for any indication were identified through the electronic medical record system. Patients were excluded if they received prophylactic rather than therapeutic doses of enoxaparin, had a creatinine clearance <30 mL/min/1.73 m² at initiation, or had missing or improperly timed anti-factor Xa measurements (not collected 4–6 hours post-dose at steady state).
This study was based on a structured retrospective chart review. Demographic data including age, gender, and weight were collected. Clinical data such as enoxaparin indication and level of admission whether to general wards or to PICU (Pediatric Intensive Care Unit) were investigated. Anti-factor Xa and serum creatinine (mmol/L) levels were extracted. Information related to anticoagulation therapy was also gathered, including the initial enoxaparin dose (mg/kg), any dose adjustments, and the final dose that achieved therapeutic range.
Anti-Xa levels were considered therapeutic if they fell within 0.5 to 1.0 IU/mL, and were drawn 4 to 6 hours after the third or fourth dose (steady state). Bleeding events were documented and categorized as major or minor as per clinical documentation by main responsible physician.
Descriptive statistics were applied to summarize the data. Categorical variables were reported as counts and percentages, while continuous variables were presented as means and standard deviations (SD). The chi-square test (χ²) or Fisher’s exact test was used to compare categorical variables, and the independent t-test or Mann–Whitney U test was used for continuous variables depending on normality.
Binary logistic regression analysis was performed to identify independent predictors of achieving therapeutic anti-Xa levels. A backward stepwise selection method was applied. Associations were expressed as unstandardized regression coefficients (β), odds ratios (ORs), and their corresponding 95% confidence intervals (CIs). A p-value <0.05 was considered statistically significant.
Results
sdfsdf
| Country | Year | Rank | Total | S1: Demographic Pressures | S2: Refugees and IDPs | C3: Group Grievance |
| Somalia | 2023 | 1st | 111.9 | 10.0 | 9.0 | 8.7 |
| Yemen | 2023 | 2nd | 108.9 | 9.6 | 9.6 | 8.8 |
| South Sudan | 2023 | 3rd | 108.5 | 9.7 | 10.0 | 8.6 |
| Congo Democratic Republic | 2023 | 4th | 107.2 | 9.7 | 9.8 | 9.4 |
| Syria | 2023 | 5th | 107.1 | 7.4 | 9.1 | 9.1 |
| Afghanistan | 2023 | 6th | 106.6 | 9.2 | 8.6 | 8.3 |
| Sudan | 2023 | 7th | 106.2 | 8.8 | 9.6 | 9.3 |
| Central African Republic | 2023 | 8th | 105.7 | 9.3 | 9.5 | 8.1 |
| Chad | 2023 | 9th | 104.6 | 9.5 | 9.0 | 8.1 |
| Haiti | 2023 | 10th | 102.9 | 8.8 | 7.7 | 5.5 |
| Ethiopia | 2023 | 11th | 100.4 | 9.8 | 9.5 | 8.9 |
| Myanmar | 2023 | 12th | 100.2 | 7.0 | 9.2 | 9.7 |
| Mali | 2023 | 13th | 99.5 | 8.8 | 8.5 | 8.5 |
| Guinea | 2023 | 14th | 98.5 | 8.8 | 6.2 | 9.4 |
| Nigeria | 2023 | 15th | 98 | 9.6 | 6.4 | 8.6 |
asda
QA check.
Discussion
This single-center retrospective chart review evaluated the appropriateness of initial enoxaparin treatment dosing in achieving therapeutic anti-factor Xa (anti-Xa) levels among pediatric patients aged ≤16 years. The findings reveal a substantial proportion of subtherapeutic responses, defined as anti-Xa levels below the therapeutic target range of 0.5–1.0 IU/mL following guideline-directed initial dosing, particularly among neonates and infants. These results corroborate the growing body of evidence indicating age-dependent variability in enoxaparin pharmacokinetics and highlight the need for tailored dosing approaches in younger pediatric subpopulations.
Despite adherence to empirically derived dosing guidelines such as those from the CHEST/ and the American Society of Hematology (ASH), only 35.3% of patients in this cohort attained therapeutic anti-Xa levels after the initial doses. This is consistent with findings from Tawajari et al., who reported that only 32% of pediatric patients achieved target levels using standardized protocols, particularly among those under two months of age. Similarly, Nagy et al. observed that younger children, especially neonates, frequently required 2.02 mg/kg ± 0.44 higher-than-recommended doses to achieve target anticoagulant activity.
The current study identified a significant association between age and anti-Xa response (p = 0.015), whereby younger patients, particularly neonates and infants exhibited lower anti-Xa levels compared to older children receiving similar weight-based dosing. Malowany et al. (2008) demonstrated that infants aged ≤2 months required significantly higher therapeutic enoxaparin doses (2.24 mg/kg every 12 hours) compared to children aged >2 months (1.48 mg/kg every 12 hours), highlight the necessity for age-stratified dosing strategies in pediatric anticoagulation. Similarly, Schloemer et al. (2014) reported a clear age-dependent decline in therapeutic requirements, with median doses of 1.5 mg/kg in neonates ≤60 days, 1.37 mg/kg in infants aged 60 days to <1 year, 1.01 mg/kg in children aged 1–13 years, and 0.99 mg/kg in adolescents aged 13–19 years. Furthermore, Sanchez de Toledo et al. (2010), in a cardiac intensive care cohort, observed a statistically significant increase in therapeutic dosing requirements among younger patients, with mean doses escalating from 1.50 mg/kg to 2.37 mg/kg every 12 hours (p = 0.02), while older pediatric patients required an increase from 1.23 mg/kg to 1.82 mg/kg every 12 hours (p = 0.002). Collectively, these findings provide strong evidence that younger pediatric subpopulations, particularly neonates and infants, exhibit distinct pharmacokinetic profiles requiring substantially higher enoxaparin doses to achieve therapeutic anti-Xa levels when compared to older children and adolescents.
In the present study, the observed mean initial enoxaparin dose of 1.06 ± 0.21 mg/kg was increased to a mean therapeutic dose of 1.44 ± 0.86 mg/kg following dose adjustment (p < 0.001). This escalation reflects the clinical need for individualized dosing in pediatric patients to achieve target anti-Xa levels. The dose increase was particularly evident in children aged 1–5 years, who required the highest adjustment (from 1.00 ± 0.08 mg/kg to 1.71 ± 1.54 mg/kg; p=0.022). Neonates (<1 month) and infants aged 1–2 months also required significant adjustments, reaching therapeutic doses of 1.69 ± 0.54 mg/kg (p= 0.051) and 1.54 ± 0.39 mg/kg (p < 0.001), respectively. Infants aged 3–12 months showed moderate escalation (1.43 ± 0.44 mg/kg; p= 0.006), while adolescents (6–16 years) demonstrated the lowest dose modification, achieving a mean therapeutic dose of 1.06 ± 0.22 mg/kg (p=0.030). These findings highlight age-dependent pharmacokinetic differences in enoxaparin metabolism and support the need for close monitoring and individualized titration, particularly in younger age groups.
Importantly, while dose escalation was necessary in a majority of patients, the safety profile of enoxaparin remained favorable. According to clinical documentation, minor bleeding events occurred in 8.8% of the cohort, with no major bleeding episodes reported. One case (1%) of heparin-induced thrombocytopenia (HIT) was reported, in line with known low incidences of HIT in the pediatric population. These findings are comparable to published literature indicating that treatment-dose enoxaparin is generally well tolerated in children, even when higher doses are required to achieve therapeutic anti-Xa levels.
Additionally, the mean time to achieve therapeutic anti-Xa levels was 7.2 ± 13.7 days, with notable variability among age groups. Infants aged 1–2 months required the longest duration (12.56 ± 28.42 days; p < 0.001), followed by infants aged 3–12 months (6.88 ± 4.54 days; p = 0.006) and children aged 1–5 years (6.86 ± 7.27 days; p = 0.022). Neonates aged <1 month (4.00 ± 2.60 days; p = 0.051) and adolescents aged 6–16 years (4.64 ± 3.10 days; p = 0.030) achieved therapeutic levels more rapidly. Such delays in attaining therapeutic anticoagulation among younger patients raise clinical concerns, particularly in critically ill populations or those with a high thrombotic burden. Although this study did not evaluate clinical outcomes associated with delayed therapeutic achievement, previous literature suggests that prolonged subtherapeutic anticoagulation may increase the risk of thrombus propagation or recurrence, emphasizing the importance of timely dose optimization in pediatric practice.
Thrombus resolution, assessed through Magnetic Resonance Imaging (MRI), Ultrasound (Doppler), CT angiography, and clinical evaluation, occurred at a mean of 68.6 ± 69.5 days, with substantial intergroup variation. The shortest mean resolution time was observed in children aged 1–5 years (58 ± 54.40 days), followed by neonates (64.75 ± 57.99 days) and infants aged 3–12 months (62.13 ± 89.65 days). In contrast, infants aged 1–2 months (78.12 ± 81.63 days) and adolescents aged 6–16 years (75.48 ± 62.01 days) experienced longer resolution times. Although no statistically significant difference was identified between age groups, early attainment of therapeutic anti-Xa levels may still influence clinical outcomes. Larger prospective studies are warranted to further elucidate the relationship between the timing of anticoagulation and thrombus resolution in pediatric patients.
Prescribing patterns revealed that the majority of enoxaparin use originated from intensive care (42.2%) and hematology (34.3%) services, highlight the high-risk, complex nature of the pediatric population requiring therapeutic anticoagulation.
Conclusions
This retrospective analysis highlights the limitations of guideline-recommended enoxaparin dosing in achieving therapeutic anti-Xa levels among pediatric patients, particularly in neonates and infants. A significant proportion of patients remained subtherapeutic after initial dosing, necessitating upward titration to attain effective anticoagulation. These findings highlight the critical need for individualized dosing strategies that account for age-specific pharmacokinetic variability, especially in younger age groups where clearance is enhanced and standard weight-based dosing proves insufficient.
Despite the necessity for dose escalation, the safety profile of enoxaparin remained acceptable, with low incidence of bleeding and HIT (Heparin-Induced Thrombocytopenia). Routine anti-Xa monitoring remains essential for dose optimization, ensuring therapeutic efficacy while minimizing the risk of adverse outcomes. Future prospective studies are warranted to develop evidence-based pediatric dosing algorithms that integrate developmental pharmacology and achieve timely therapeutic targets across all age strata.
References
- Altuwayjiri A, AlDarwish A, Alshuraim R. An evaluation of the appropriateness of initial enoxaparin dosing among pediatric patients. Cureus. 2023;15(11):e48830.
- Bauman ME, Belletrutti MJ, Bajzar L, Black KL, Kuhle S, Bauman ML, et al. Evaluation of enoxaparin dosing requirements in infants and children: Better dosing to achieve therapeutic levels. Thromb Haemost. 2009;101(1):86–92.
- Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):188S–203S.
- Ignjatovic V, Furmedge J, Newall F, Chan A, Berry L, Fong C, et al. Age-related differences in heparin response. Thromb Res. 2006;118(6):741–745.
- Malowany JI, Monagle P, Knoppert DC, Lee DS, Wu J, McCusker P, et al. Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates. Thromb Res. 2008;122(6):826–830.
- Moffett BS, Lee-Kim Y, Galati M, Mahoney D, Shah MD, Teruya J, et al. Population pharmacokinetics of enoxaparin in pediatric patients. Ann Pharmacother. 2018;52(2):140–146.
- Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, et al. Antithrombotic therapy in neonates and children: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e737S–e801S.
- Monagle P, Cuello CA, Augustine C, Bonduel M, Brandão LR, Capman T, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Treatment of pediatric venous thromboembolism. Blood Adv. 2018;2(22):3292–3316.
- Nagy R, Hemmelgarn T, Deptola S, Hemmann B. Evaluation of initial enoxaparin dosing and antifactor Xa levels in infants admitted to the neonatal intensive care unit. Biomed Hub. 2024;9(1):54–61.
- Sanchez de Toledo J, Gunawardena S, Munoz R, Orr R, Berry D, Sonderman S, et al. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit? Cardiol Young. 2010;20(2):138–143.
- Schloemer NJ, Abu-Sultaneh S, Hanson SJ, Yan K, Hoffmann RG, Punzalan RC, et al. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children. Pediatr Crit Care Med. 2014;15(7):e294–e299.
- Wysocki EL, Kuhn A, Steinbrenner J, Tyrrell L, Abdel-Rasoul M, Dunn A, et al. Enoxaparin dose requirements to achieve therapeutic low-molecular-weight heparin anti-factor Xa levels in infants and young children. J Pediatr Hematol Oncol. 2021;43(7):e946–e950.